logo-loader
viewReNeuron Group PLC

ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE) updates Proactive on their phase II clinical study treating stroke patients with its CTX stem cells.

Hunt says the positive response rates reported at three months after treatment were sustained at 12 months after treatment, with seven people still showing a “clinically relevant improvement”.

Quick facts: ReNeuron Group PLC

Price: 109 GBX

LSE:RENE
Market: LSE
Market Cap: £34.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read